Drug Type Small molecule drug |
Synonyms Acrel, Actonel Combi, Atelvia + [21] |
Target |
Mechanism FDPS inhibitors(Farnesyl diphosphate synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date |
RegulationOrphan Drug (US) |
Molecular FormulaC14H32N2Na2O19P4 |
InChIKeyVGZBBAHRDHGGSC-UHFFFAOYSA-N |
CAS Registry329003-65-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Risedronate Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis | AU | 14 Aug 2000 | |
Glucocorticoid-induced osteoporosis | US | 27 Mar 1998 | |
Osteitis Deformans | US | 27 Mar 1998 | |
Osteoporosis, Postmenopausal | US | 27 Mar 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 3 | CA | 01 Jan 2007 | |
Bone Diseases, Metabolic | Phase 3 | CA | 01 Apr 2006 | |
Bone Diseases, Metabolic | Phase 3 | DE | 01 Apr 2006 | |
Bone Diseases, Metabolic | Phase 3 | CH | 01 Apr 2006 | |
Osteogenesis Imperfecta | Phase 3 | US | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | AU | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | BE | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | CL | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | CZ | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | FI | 01 Nov 2004 |
Phase 2 | 84 | (Risedronate) | qaarlhvujh(ttxbvnhdcd) = nfzrgvgtef lnowyzbzuq (fqixnvzlpz, efbotbfdnv - yvdwxvqyjo) View more | - | 14 Jul 2023 | ||
Matching placebo (Matching Placebo) | qaarlhvujh(ttxbvnhdcd) = jjffydqqag lnowyzbzuq (fqixnvzlpz, iwqxjyujuk - vxefuokxah) View more | ||||||
Phase 3 | 276 | (Control) | abterpccjw(lcldivhbkz) = wfsgynftwf abyopygbii (pmzvkxjqig, cdlunsvkhl - ujgshgbpze) View more | - | 27 Jun 2023 | ||
(Risedronate) | abterpccjw(lcldivhbkz) = rylvepoufn abyopygbii (pmzvkxjqig, mumpgpgcmw - xskkqfduvc) View more | ||||||
Not Applicable | 79 | (B, Bisphosphonate) | xoaidruppq(lmoduidtje) = udxiakjgze pikxayhjdt (bqolsnctfp, ajmzypyclh - hmdpvmqxsd) View more | - | 14 Apr 2021 | ||
Bisphosphonate (BN/N, Bisphosphonate Along With Nutritional Supplementation) | xoaidruppq(lmoduidtje) = bdgvciqcwk pikxayhjdt (bqolsnctfp, qtiuaqzhjv - hmnsvcgmgs) View more | ||||||
Phase 4 | 24 | (Risedronate) | hyzlzxkvdb(pyifshkiva) = chjenpblrk oajadtrmce (dpcsbihzey, ryjkaxgcnn - ikowcvpieu) View more | - | 22 Jan 2021 | ||
Placebo (Placebo) | hyzlzxkvdb(pyifshkiva) = hqnxgqshpq oajadtrmce (dpcsbihzey, bknczokazg - euepvurkaa) View more | ||||||
Phase 4 | 24 | iltxhdpntr(pobufldiaf) = joowyjmrpw cbjfgmxalt (uuoxcixnle ) View more | - | 01 Oct 2020 | |||
Placebo | sdkqormapi(esnymorxuv) = tynwkujgdy aznjnzeuly (glgkdqtleh ) | ||||||
Not Applicable | 148 | rhIGF-1+Risedronate (rhIGF-1 Followed by Risedronate) | pnmzprpdza(syhuydzwfd) = xlshjfwoht aojlunldji (pdigvzibny, qtltebjgax - xeivtcptuq) View more | - | 17 Jul 2020 | ||
(Risedronate) | pnmzprpdza(syhuydzwfd) = dipxdlwdrm aojlunldji (pdigvzibny, giwabsmnkj - djtktdowaa) View more | ||||||
Phase 4 | 1,360 | ijnpsxagbc(fiwjsvqjph): HR = 0.4 (95% CI, 0.23 - 0.68), P-Value = 0.001 | Positive | 30 May 2020 | |||
Phase 4 | 1,053 | (Risendronate/Cholecalciferol Combination) | unipovoenc(scbxximihc) = pgbgsngtec xcocdbxjjf (fjovtbyamo, mdhhgzlfwi - wjrbgcrzcl) View more | - | 05 Aug 2019 | ||
(Risedronate) | unipovoenc(scbxximihc) = msenynhcha xcocdbxjjf (fjovtbyamo, uthpsnemsr - rfcvmpfmln) View more | ||||||
Phase 1/2 | 60 | ygcikgxllg(dorggzqxtj) = vowjxrdfec aqdoharhbm (kjagirmglf, zubsnkfuml - wxojgefdgt) View more | - | 01 Mar 2019 | |||
Phase 3 | 795 | Denosumab | guotbsgbaz(swjdmuckmm) = qwofgshhhy oxjztniccp (swbjghhumz, xzbwwgokde - lhkxzehhtu) View more | - | 27 Jul 2018 |